AMRX News and Press, Amneal Pharmaceuticals Inc. Class A From 03/30/22

Amneal Pharmaceuticals shares have fallen in value from $24 to $4 since September 2018. That's due to a merger with Impax which led to heavy losses but also gave the company the opportunity to gain access to the public markets. After the founders stepped away for most of the troub...

- First presentation at a medical meeting of topline results and post hoc analysis - Positive topline results were previously announced in August 2021 Amneal Pharmaceuticals, Inc. (NYSE: AMRX) today announced that results from the pivotal Phase 3 RISE-PD clinical tri...

Medicines Patent Pool (MPP) announced on Thursday that nearly three dozen companies signed agreements to manufacture the generic versions of the oral COVID-19 therapy developed by Pfizer (NYSE:PFE). The sublicence agreements follow a voluntary licensing agreement signed by MPP and Pfizer (PFE...

- One of 35 global companies selected to manufacture and commercialize generic version of COVID-19 treatment Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced it has been awarded a sub-license from the Medicines...

Amneal Pharmaceuticals Inc. (AMRX) Q4 2021 Earnings Conference Call March 2, 2022 8:30 am ET Company Participants Chirag Patel - President, Co-Chief Executive Officer Chintu Patel - Co-Chief Executive Officer Tasos Konidaris - Chief Financial Officer Joe Todisco - Chief Commercial Officer, Sp...

Amneal Pharmaceuticals (AMRX -8.3%) stock declined following its mixed Q4 results and and non-GAAP EPS guidance below estimates. Q4 revenue rose +5.27% Y/Y to $536.9M, beating estimates. The increase was driven by Generic new product launches and growth in the company's promoted Specialt...

The following slide deck was published by Amneal Pharmaceuticals, Inc. in conjunction with their 2021 Q4 earnings call. For further details see: Amneal Pharmaceuticals, Inc. 2021 Q4 - Results - Earnings Call Presentation

Amneal Pharmaceuticals press release (NYSE:AMRX): Q4 Non-GAAP EPS of $0.18 misses by $0.02. Revenue of $537M (+5.3% Y/Y) beats by $3.59M. Provides 2022 Financial Guidance of $2.15 to $2.25 billion ($2.15B consensus) in net revenue and $540 to $560 million in adjusted EBITDA. Adjusted diluted ...

‒ Q4 2021 Net Revenue of $537 million; GAAP Net Loss of $6 million; Diluted Loss per Share of $0.04 ‒ ‒ Q4 2021 Adjusted Net Income of $54 million (1) , Adjusted EBITDA (1) of $126 million; Adjusted Diluted EPS (1) of $0.18 ‒ &...

Amneal Pharmaceuticals (NYSE:AMRX) said the U.S. FDA approved its Biologics License Application (BLA) for filgrastim-ayow, a biosimilar referencing Neupogen. The product will be marketed under the proprietary name RELEUKOTM. RELEUKOTM was developed in collaboration with Kashiv Biosciences in ...